Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise

Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise

A new CMS interim final rule on Medicaid work requirements could force cancer patients, including those in active treatment, to meet work hours as a condition of coverage, contradicting earlier legislative promises. This development has significant implications for patient access to oncology therapies and for pharmaceutical market access strategies.

Key Takeaways

• CMS released an interim final rule on June 4, 2026, that imposes work requirements on Medicaid beneficiaries without a blanket exemption for cancer patients, despite legislative assurances during the 2025 reconciliation bill debate.
• More than 2 million Americans with cancer rely on Medicaid, including 1 in 3 children with a cancer history; coverage interruptions at any scale would reduce utilization of branded oncology therapies and disrupt treatment regimens.
• Pharma BD and market access teams should model state-level implementation variation, reassess patient assistance program eligibility criteria, and prepare for potential revenue headwinds in franchises with high Medicaid exposure.

What did lawmakers promise — and what did CMS actually do?

Throughout the 2025 reconciliation bill debate, lawmakers publicly assured patient advocates that cancer patients undergoing treatment would be exempt from any new Medicaid work requirements. The KFF analysis of the bill's Medicaid provisions had flagged work requirements as a major risk for vulnerable populations, but those concerns were met with pledges that cancer patients would not be affected.

On June 4, 2026, CMS released an interim final rule with no blanket exemption for active cancer treatment. A patient receiving myelosuppressive chemotherapy who cannot maintain part-time employment could lose coverage mid-cycle. The rule's text makes no distinction between a healthy beneficiary and one with metastatic disease undergoing second-line immunotherapy. That gap between legislative promise and regulatory reality is now a central liability for oncology market access.

How many cancer patients rely on Medicaid — and what is at stake for pharma?

Medicaid covers more than 2 million Americans with cancer, according to STAT reporting on the rule's impact. That includes 1 in 10 adults and 1 in 3 children with a cancer history. These numbers represent concentrated exposure for pharma companies: a coverage interruption of even 10–15% of that population would translate into measurable volume loss across multiple indications, particularly in hematologic malignancies, breast cancer, and pediatric oncology where Medicaid enrollment is disproportionately high.

The Cancer Leadership Council has urged lawmakers to protect coverage for patients who depend on it, but the CMS rule signals that those appeals have not prevailed at the federal level. For pharma government affairs teams, the window for a legislative fix is narrow — the rule takes effect on a timeline that could produce coverage terminations before Congress can act.

What should pharma teams prepare for?

BD and market access teams should run scenario analyses at the state level, because implementation will not be uniform. Some states will craft their own medical exemptions for cancer patients; others will adopt the federal rule as written. That patchwork will directly affect patient assistance program eligibility, co-pay accumulator strategies, and contracting for oncology products in state Medicaid formularies.

Investor analysts should treat this as a potential revenue headwind not yet reflected in consensus estimates. Oncology franchises with the highest Medicaid exposure — particularly in immuno-oncology and rare pediatric cancers — face the most acute risk. The rule introduces a new variable into forecast models that most companies have not addressed in their 2027 guidance.

Patient advocacy groups, including the Cancer Leadership Council, have signaled they will continue to push for exemptions at both the federal and state level. Pharma teams should align with those efforts, but also build operational contingency plans that assume coverage losses will materialize in at least some states within the next 12 months.

F

Related coverage

• STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
• Abivax Ulcerative Colitis Drug Shows Strong Efficacy, But Cases of Cancer Raise Concerns
• Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg